Poor
Major Misalignment
Patient Risk:
High
Summary
Multiple claims are contradicted or not supported by the provided FDA label excerpts, including fat-soluble vitamin absorption reductions and vitamin deficiency risk, plus several adverse effect generalizations not present in the label. Critical label sections (e.g., contraindications, boxed warnings, full safety) are not evaluated and appear omitted.
Category Scores
Accurate Statements
Ezetimibe works by blocking the absorption of cholesterol in the small intestine.
12.1 Mechanism of Action: reduces blood cholesterol by inhibiting absorption of cholesterol by the small intestine.
Ezetimibe reduces cholesterol absorption by approximately 50%.
12.2 Pharmacodynamics: inhibited intestinal cholesterol absorption by 54% (approximation is directionally consistent).
When used with a statin, ezetimibe can be more effective at reducing cholesterol levels than a statin alone.
14 CLINICAL STUDIES: combination with statins significantly lowers LDL-C compared with statin alone (including ongoing statin therapy and concurrent initiation).
Combination therapy (ezetimibe plus simvastatin) is more effective at reducing LDL cholesterol levels than simvastatin alone.
14 CLINICAL STUDIES, Table 9: LDL-C reductions are greater with ZETIA + simvastatin than with simvastatin alone.
Ezetimibe can cause abdominal pain.
6.2 Post-Marketing Experience: gastrointestinal disorders include abdominal pain.
Rare but serious side effects of ezetimibe include muscle pain and weakness.
5.3 Myopathy/Rhabdomyolysis: ZETIA may cause myopathy including muscle pain, tenderness, or weakness (label highlights serious risk context, though provided excerpt does not support the word 'rare').
Ezetimibe is available under the brand name Zetia.
INDICATIONS AND USAGE: ZETIA is the brand referenced for ezetimibe.
Unsupported Statements
Ezetimibe reduces absorption of triglycerides by approximately 30%.
No triglyceride absorption reduction percentage is provided in the supplied label excerpts.
Ezetimibe is effective at reducing the absorption of other types of dietary fats, including triglycerides and fat-soluble vitamins.
Label supports cholesterol absorption inhibition and states no clinically meaningful effect on plasma fat-soluble vitamin concentrations; triglyceride absorption reduction is not supported.
The most common side effect of ezetimibe is gastrointestinal upset.
The provided label excerpts do not state 'most common' adverse event or identify gastrointestinal upset as the most common side effect.
Ezetimibe can cause diarrhea.
Diarrhea is not listed in the supplied adverse reaction excerpts.
Ezetimibe can cause constipation.
Constipation is not listed in the supplied adverse reaction excerpts.
Muscle pain and weakness are particularly noted when ezetimibe is used in combination with a statin.
The supplied excerpt does not state that muscle pain/weakness are 'particularly' noted with combination use; it states post-marketing rhabdomyolysis cases were often on statin or other agents.
The patent for Zetia expired in 2017, allowing generic versions of the medication to become available.
Patent/generic availability timing is not present in the supplied label excerpts.
The patent for ezetimibe itself expires in 2030.
Patent-expiration timing is not present in the supplied label excerpts.
Contradictions
High
AI Statement
Ezetimibe decreases the absorption of fat-soluble vitamins by approximately 25%.
Label Reference
12.2 Pharmacodynamics: states no clinically meaningful effect on plasma concentrations of fat-soluble vitamins A, D, and E (no ~25% reduction supported).
High
AI Statement
Ezetimibe decreases absorption of fat-soluble vitamins, particularly vitamin A, by approximately 25%.
Label Reference
12.2 Pharmacodynamics: states no clinically meaningful effect on plasma concentrations of fat-soluble vitamins A, D, and E.
High
AI Statement
Ezetimibe use is associated with potential for vitamin deficiencies.
Label Reference
12.2 Pharmacodynamics: no clinically meaningful effect on plasma concentrations of fat-soluble vitamins A, D, and E.
High
AI Statement
Ezetimibe use is associated with potential for vitamin A and D deficiencies.
Label Reference
12.2 Pharmacodynamics: no clinically meaningful effect on plasma concentrations of fat-soluble vitamins A, D, and E.
Important Omissions
Contraindications (section 4) were not assessed/mentioned in the extracted claims.
Importance:
High
Boxed warnings (if any) were not assessed/mentioned.
Importance:
High
Pregnancy and lactation risk/wording (sections 8.1 and 8.2) were not assessed/mentioned.
Importance:
High
Relevant safety monitoring guidance for clinically important risks (e.g., liver enzyme testing/withdrawal criteria when used with statins; myopathy/rhabdomyolysis management) was not assessed/mentioned.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Contradicted safety-related claims about fat-soluble vitamin absorption and vitamin A/D deficiency potential (12.2) plus unsupported broad adverse effect generalizations and missing evaluation of contraindications/boxed warnings/pregnancy-lactation/monitoring increase label miscommunication risk.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Major Misalignment
Primary Issue
Several high-impact claims directly contradict 12.2 (no clinically meaningful effect on fat-soluble vitamins A, D, E) and multiple other claims are unsupported by the provided label excerpts.
Suggested Improvement
Remove or correct vitamin absorption/vitamin deficiency claims, avoid unlabelled AE frequency/generalization (e.g., 'most common', diarrhea/constipation), and restrict efficacy statements to those supported in 14 clinical study tables. Additionally, include evaluation of contraindications, boxed warnings, pregnancy/lactation, and monitoring language where relevant.